This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Health Stocks in Motion

Updated from 2:19 p.m. EST

Shares of NitroMed (NTMD) were among the worst-performing health-related stocks Friday, falling 12.8% after the company posted a fourth-quarter loss that just missed expectations.

The company posted a loss of $9.7 million, or 36 cents a share, on sales of $9.5 million. Analysts polled by Thomson First Call were expecting a loss of 35 cents a share. A year ago, the company posted a loss of $10.5 million, or 71 cents a share, on sales of $7.2 million. Shares traded down $2.73 to $18.62.

Horizon Health (HORC) rose 9.7% after the company said it priced 1.5 million shares at $36.25 each in a follow-on stock offering. The stock closed Thursday at $36.40. Horizon said that it would use the $50.6 million in net proceeds to pay down $34.5 million in debt and use the rest for general corporate purposes, including acquisitions. J.P. Morgan led the underwriting syndicate. Shares traded up $3.52 to $39.92.

Shares of Nanogen (NGEN) rose 4.1% after the company said it received a patent related to ligation-based strand displacement amplification technology, which will make the detection of infectious diseases much quicker. The intellectual property pertains to research that was conducted in collaboration with Becton Dickinson (BDX). Shares traded up 16 cents to $4.10.

Savient Pharmaceuticals (SVNT) traded actively after the company halted a phase II clinical trial for its Prosaptide compound. The trial was designed to test the safety and efficacy of the drug in HIV and AIDS patients who suffered from peripheral neuropathic pain. The trial was halted at the recommendation of the Data and Safety Monitoring Board, which discussed the results of the analysis of the unblended study at a meeting in late February. On March 10, the safety monitoring board wrote a letter to Savient, saying that even if the trial were to continue, there was little chance of achieving statistical significance at the analgesia efficacy endpoint. Shares traded up 10 cents to $2.64 on volume of more than 1.15 million shares.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs